** Shares of Divi's Laboratories DIVI.NS rise 3% to 6,561 rupees, its biggest jump in three months
** Brokerage Citi says 2026 can be an inflection year for DIVI, calls it their 'top' pharma pick in India
** Adds co has strong pipeline catalysts over the next 12 months; generic segment expected to witness a recovery
** Expcts co's revenue to expand by 3 times and EBITDA to rise 4 times over FY25-FY30e
** Citi has a "buy" rating on co with PT at 9,140 rupees
** DIVI rated "hold" on avg by 27 analysts covering it; median PT at 6780 rupees - data compiled by LSEG
** In 2025, DIVI gained ~5%
(Reporting by Komal Salecha)
((Komal@thomsonreuters.com;))